Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
NovoCure's Capital Expenditure for the
three
months ended in Mar. 2022 was $-5.09 Mil. Its Revenue for the
three
months ended in Mar. 2022 was $137.55 Mil.
Hence, NovoCure's Capex-to-Revenue for the
three
months ended in Mar. 2022 was 0.04.
NovoCure Capex-to-Revenue Historical Data
The historical data trend for NovoCure's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovoCure Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Capex-to-Revenue
0.04
0.03
0.03
0.03
0.05
NovoCure Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Capex-to-Revenue
0.03
0.02
0.03
0.11
0.04
Competitive Comparison
For the Medical Instruments & Supplies subindustry, NovoCure's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Capex-to-Revenue Distribution
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where NovoCure's Capex-to-Revenue falls into.
NovoCure Capex-to-Revenue Calculation
NovoCure's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (NAS:NVCR) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
NovoCure Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of NovoCure's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
4.6(6.09%) Volume: 523,365 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:NVCR has been successfully added to your 
